Ranexa(R) Added To New ACC/AHA Guidelines On Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)

CV Therapeutics,
Inc. (Nasdaq: CVTX) announced today that new guidelines, developed jointly
by the American College of Cardiology Foundation and the American Heart
Association and published in this week's issue of Circulation, state that,
"ranolazine may be safely administered for symptom relief after UA/NSTEMI."



Ranexa(R) (ranolazine extended-release tablets) is indicated for the
treatment of chronic angina in patients who have not achieved an adequate
response with other antianginal drugs, and should be used in combination
with amlodipine, beta-blockers or nitrates. The product has not been
determined by regulatory authorities to be safe and effective for any other
use.



About CV Therapeutics



CV Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company focused on applying molecular cardiology to the
discovery, development and commercialization of novel, small molecule drugs
for the treatment of cardiovascular diseases.



CV Therapeutics' approved product, Ranexa(R) (ranolazine
extended-release tablets), is indicated for the treatment of chronic angina
in patients who have not achieved an adequate response with other
antianginal drugs, and should be used in combination with amlodipine,
beta-blockers or nitrates.



CV Therapeutics' clinical and preclinical drug development candidates
and programs, including regadenoson, which is being developed for potential
use as a pharmacologic stress agent in myocardial perfusion imaging
studies, and CVT-6883, which is being developed as a potential treatment
for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been
determined by any regulatory authorities to be safe or effective in humans
for any use.



Except for the historical information contained herein, the matters set
forth in this press release, including statements as to treatment
guidelines, are forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially, including operating
losses and fluctuations in operating results; capital requirements;
regulatory review and approval of our products; special protocol assessment
agreement; the conduct and timing of clinical trials; commercialization of
products; market acceptance of products; product labeling; concentrated
customer base; and other risks detailed from time to time in CV
Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for
the quarter ended June 30, 2007. CV Therapeutics disclaims any intent or
obligation to update these forward-looking statements.


CV Therapeutics, Inc.

cvt